Object. The well-known predictors for increased early deaths after spontaneous intracerebral hemorrhage (ICH) include the clinical and radiological severity of bleeding as well as being on a warfarin regimen at the onset of stroke. Ischemic heart disease and atrial fibrillation may also increase early deaths. In the present study the authors aimed to elucidate the role of the last 2 factors.
RIMARY ICH is a devastating disease with high rates of early mortality. 18 Efforts to identify factors that could be targeted to decrease death rates have recently increased. 4, 6, 9, 13, 16, 21 Many studies have concentrated on the laboratory, radiological, and clinical parameters assessed on admission. In particular, early hematoma growth has been found to be a major factor leading to early death. 4 A few studies have accounted for existing comorbidities, such as cardiac diseases and diabetes.
Investigators in 2 studies have found diabetes to be an independent predictor for early death after ICH, 1, 29 whereas the role of cardiac diseases has remained less clear. In 1 population-based study, heart disease (coronary artery disease or atrial fibrillation) was found to be an independent predictor for early death. 16 On the other hand, ischemic heart disease (coronary artery disease with or without previous MI) was not found to be an independent risk factor for early death in 3 hospital-based studies. 19, 20, 29 In our previous study, regular aspirin use or anticoagulant treatment preceding ICH independently predicted death. 21 Both antiplatelet agents and anticoagulants are commonly used in secondary prevention of cardiovascular diseases. Consequently, the use of these agents may have emerged as a risk factor for death after ICH due to a proxy effect of several factors associated with their use, including the patient's age, presence of diabetes, and history of cardiac disease or ischemic stroke. We conducted this study to resolve the role of cardiac diseases as risk factors for death after ICH.
Clinical Materials and Methods

Patient Population
The study series comprised all patients with ICH admitted between January 1993 and January 2004 to the Department of Neurology of Oulu University Hospital, Finland, which is the only hospital serving patients suffering acute stroke in Northern Ostrobothnia (population 373,868 as of December 31, 2003) . We excluded the patients not residing Impact of ischemic heart disease and atrial fibrillation on survival after spontaneous intracerebral hemorrhage in the hospital's catchment area; those with bleeding caused by a brain tumor, aneurysm, vascular malformation, hematological malignancy, coagulation disorder, or head trauma; and those admitted to the other departments of the hospital. The patients admitted to the other departments had one of the aforementioned diseases or needed immediate surgery. The ethics committee of the hospital approved the study protocol.
The presence of ICH was verified by using head CT scanning in all cases, and the follow-up brain images (CT or magnetic resonance imaging studies) obtained ~ 3 months after the bleeding episode were searched for secondary structural abnormalities. Angiography was performed if the location of ICH suggested the presence of an aneurysm. After admission, a second head CT scan was obtained within 2 weeks for 288 patients, including the 213 who showed early clinical deterioration (but excluding those who were already moribund on admission).
The time of ICH onset was defined by the acute onset of headache or a neurological deficit. Data about comorbidities, blood pressure histories, medications, and health habits were extracted from the hospital records. Patients were considered to be hypertensive if their blood pressure readings preceding ICH had exceeded 160/90 mm Hg at least twice (according to the World Health Organization/International Society of Hypertension statement 28 ), or if they were taking antihypertensive medication. Patients were recorded as having diabetes mellitus if they used oral antihypoglycemia agents or insulin. Previous hemorrhagic (ICH and subarachnoid hemorrhage) and ischemic (including transient ischemic attacks) strokes were recorded. Previous MI and coronary artery disease were recorded as ischemic heart disease. Atrial fibrillation was recorded if present on arrival at the hospital. Lifestyle factors such as current cigarette smoking and recent heavy drinking were elicited from hospital records. Recent heavy drinking was defined as weekly ingestion of at least 300 g of ethanol during the month preceding the stroke, which data were obtained by interviewing patients and/or their relatives. The patients' survival during the first 3 months after the onset of ICH was checked according to hospital records and death records obtained from the Registry for Causes of Death by Statistics Finland. Autopsy records were also checked.
All CT scans were examined and the locations and volumes of hematomas were measured by an experienced neuroradiologist (J.P.) who was unaware of the patients' case histories. Hematomas were divided into categories based on their location. Hematoma volumes were measured on a computer workstation in accordance with the previously described principles; 3 that is, by encircling the boundaries of each hematoma with a pointer slice by slice and thereby determining its area. The area was then multiplied by slice thickness (5 mm in the posterior fossa and 10 mm supratentorially) to obtain the volume. The presence of intraventricular bleeding was recorded. Enlargement of the hematoma was assessed if a second CT scan was obtained within 2 weeks after the onset of ICH. For statistical analysis, the relative volume enlargement as a percentage of each hematoma was calculated.
Statistical Analysis
Data were analyzed using SPSS for Windows software (release 12.0.1.2003, SPSS, Inc.). For univariate analysis, conventional statistical tests were used. For life table analysis and the Cox proportional hazards regression model, each patient was followed until death or for 3 months after ICH. Cumulative survival rates were estimated using the Kaplan-Meier product-limit method, and the curves of the different groups were compared using the log-rank test. The Cox proportional hazards model with a forward stepwise regression procedure served to determine the significance of several variables in predicting hazard ratios with 95% confidence intervals for death. The following variables, which were known at the beginning of the follow-up period, were analyzed: age (continuous variable, per year); sex; history of hypertension, ischemic or hemorrhagic stroke, ischemic heart disease, diabetes, and cancer; atrial fibrillation on admission; hematoma size (continuous, per 10 ml) and location (supratentorial: subcortex, basal ganglia, putaminal thalamus, and combined; or infratentorial: cerebellum and pons); presence of intraventricular hematoma; warfarin treatment; regular aspirin use; GCS score on admission (continuous, per unit); current smoking; and recent heavy drinking. The assumption of proportionality was checked. The test for significance was based on changes in log (partial) likelihood. A two-tailed probability value of Ͻ 0.05 was considered statistically significant.
Results
Altogether, 453 patients with verified spontaneous ICH were admitted to the Department of Neurology within the study period of 11 years. The baseline characteristics of the patients are shown in Table 1 . Overall, 325 patients (72%) survived for 3 months, whereas 128 (28%) died. One hundred thirty-seven of the patients had a history of ischemic heart disease, and 54 had atrial fibrillation on admission. Hypertension, ischemic heart disease, atrial fibrillation, previous ischemic stroke, diabetes, older age, use of warfarin, and use of aspirin were significantly more common among the patients who died within 3 months after the onset of ICH.
The clinical characteristics are shown in Table 2 . The patients who died within the first 3 months had significantly larger clots, and they had intraventricular or infratentorial hematomas significantly more often, whereas in those who survived, subcortical hematomas were significantly more frequent. Hematoma enlargement occurred more frequently, and GCS scores on admission were significantly lower among the patients who died.
The cumulative survival rates for the patients with and without ischemic heart disease are shown in Fig. 1 . The 3-month survival rate of the patients with ischemic heart disease was significantly lower than that of the patients without it. Deaths were more frequent among the patients with (58 [42%] of 137) than without (70 [22%] of 316) ischemic heart disease. Thirty-one of those with ischemic heart disease were receiving warfarin treatment, 66 were receiving aspirin treatment, and 40 were receiving neither of these drugs on admission. Of those who were on a regimen of warfarin, 18 (58%) of 31 died, whereas of those who were on an aspirin regimen or who were receiving neither of these drugs, 27 (41%) of 66 and 13 (33%) of 40 died, respectively. Accordingly, those who were taking either war-farin or aspirin on admission showed a worse prognosis than those who were taking neither medication (p = 0.034).
The cumulative survival rates for the patients with and without atrial fibrillation on admission are shown in Fig. 2 . The 3-month survival rate of the patients with this condition was significantly lower than that of the patients without it. Deaths were more frequent among the patients with (33 [61%] of 54) than without (95 [24%] of 399) atrial fibrillation. Thirty of those with atrial fibrillation were receiving warfarin treatment and 24 were not. Of those with atrial fibrillation and on warfarin, 18 (60%) of 30 died, whereas of those with atrial fibrillation but not on warfarin, 15 (63%) of 24 died. The patients with atrial fibrillation on admission included 13 who were on an aspirin regimen, and 11 of them (85%) died within 3 months. They had significantly larger hematomas on admission than nonusers of either aspirin or warfarin (Mann-Whitney U-test, p = 0.011). The 2-day mortality rates of warfarin users, aspirin users, and users of neither drug were 31, 10, and 6%, respectively. The corresponding mortality rates were 45, 34, and 14% at 1 month, and 53, 38, and 18% at 3 months after ICH.
The predictors for death during the first 3 months after ICH that were found with stepwise Cox regression after adjustment for sex are shown in Table 3 . Forty-six (10%) of 453 patients died within 2 days, 108 (24%) died within 1 month, and 128 (28%) died within 3 months. The following significant independent predictors for death within the first 2 days were identified: use of warfarin, hematoma size, infratentorial location, and low GCS score. Preceding use of aspirin was not a significant predictor for early death. The significant independent predictors for death within the 1st month were the size and infratentorial location of the hematoma, intraventricular bleeding, patient age, low GCS score, atrial fibrillation on admission, and history of ischemic heart disease. Use of warfarin was an almost significant predictor for death within 1 month in multivariate analysis (p = 0.054). The significant predictors for death at 3 months were the same as those for death at 1 month.
Because both ischemic heart disease and atrial fibrillation on admission were frequently associated with the use of aspirin and warfarin, we also tested for interactions and collinearity of these factors. We did not observe any significant interactions between the history of ischemic heart disease and the use of either aspirin or warfarin, nor did we observe interactions between atrial fibrillation on admission and either aspirin or warfarin use (p values ranged from 0.36 to 0.43). After entry of the interaction terms into the model (data not shown), the significant predictors remained unchanged.
The causes of death (according to the Causes of Death Register, Statistics Finland) and the complications encountered in those who died within the first 3 months are shown in Table 4 . In this table, the patients with a history of ischemic heart disease or atrial fibrillation on admission make up the group with heart disease. The primary bleeding episode was the main cause of death, accounting for 97 (76%) of 128 deaths. However, the cause of death was verified by autopsy in only 3 patients. Cardiac complications were more frequent (16% compared with 9%) in the patients with heart disease, as anticipated.
Discussion
We found ischemic heart disease and atrial fibrillation on admission to be significant and independent predictors for death at 1 and 3 months after ICH. These factors were more significant than hypertension, diabetes, or previous ischemic stroke. On the other hand, use of warfarin was indisputably a significant predictor for death only within the first 2 days. Moreover, among the patients with ischemic heart disease or atrial fibrillation, those who were on a regimen of either warfarin or aspirin showed higher mortality rates than those who were not. The highest mortality rate (85%) was observed in the patients with atrial fibrillation on admission who were on an aspirin regimen. This is a novel finding.
Neither atrial fibrillation nor ischemic heart disease have been listed as predictors for early death in recent reviews. 14, 18 Our analyses indicated that the risk caused by heart disease was not a proxy effect of either anticoagulant or aspirin treatment. One earlier study suggested that atrial fibrillation may impair the prognosis of ICH, 17 and another reported that heart disease (coronary artery disease or atrial fibrillation) was significantly associated with 30-day and 1-year mortality rates after ICH. 16 These previous observations support our findings.
The reason why heart disease independently increased the 3-month mortality rate after ICH remains unclear. In our study, the primary bleeding episode was recorded as the cause of death in most cases, and the autopsy rate was very
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FIG. 2.
Graph showing 3-month survival of patients with ICH according to the presence or absence of atrial fibrillation on admission. The log-rank test revealed a significant difference between the survival curves (p Ͻ 0.001).
low. Many of the patients with heart disease were on a regimen of warfarin medication. Rapid enlargement of the hematoma could explain the high immediate mortality rate in these patients. However, those who were not on a regimen of warfarin and died later may have had other causes of death. The MI and cardiac complications were seen more often in the records of the patients with heart disease than in those without it. The fact that the administration of both warfarin and aspirin was discontinued on admission due to ICH may also have contributed, via cardiovascular complications, to the higher mortality rate later on in the patients with heart disease. An increased risk for deep vein thrombosis and pulmonary embolism has been observed in hospitalized patients with heart failure. 2 Due to the lack of autopsies, pulmonary embolism remained poorly diagnosed in our series. Pulmonary embolism could have contributed to the high rate of mortality, because it may manifest primarily as impaired cardiorespiratory reserve and sudden death. 12 The question of whether primary ICH may cause changes in the autonomic nervous system leading to fatal arrhythmias in patients with ischemic heart disease warrants further evaluation. Brainstem hemorrhage has repeatedly been reported to be associated with a sudden onset of atrial fibrillation. 25, 30 Warfarin use is known to increase mortality rates during the acute phase of ICH, the main reason being the rapid enlargement of the hematoma due to poor coagulation.
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Death rates Ͼ 50% during the first 3 months have been repeatedly reported. 8, [20] [21] [22] Patients on a regimen of oral anticoagulant therapy have a 7-to 10-fold higher incidence of ICH compared with those not receiving anticoagulants. 24 In Finland, the prevalence of anticoagulant treatment is relatively high. Age-adjusted prevalence has been reported to be 0.65%, 27 and nearly half of the patients take anticoagulant drugs for atrial fibrillation. 5 Preceding aspirin use did not significantly increase early deaths due to ICH in this study. Regular aspirin use may, however, act as a proxy for other factors that are likely to increase the risk of death. 7 It seems that diseases treated with aspirin may be more significant contributors to the outcome of ICH than previous aspirin use in itself. However, the patients with atrial fibrillation who were on an aspirin regimen had larger hematomas already on admission than those who were not receiving aspirin or warfarin. This suggests that the aspirin regimen may lead to rapid hematoma growth. In our previous study, 21 preexisting aspirin use was associated with large hematomas, and according to other reports, aspirin use may also be associated with rapid hematoma enlargement. 23, 26 It remains to be resolved by prospective studies whether patients who are on an aspirin regimen do have an increased risk for hematoma growth and whether this causes clinical deterioration and early death. The present study was not designed to verify early hematoma growth, and many of the patients on aspirin therapy underwent no further head CT scans because they were already moribund on admission.
The strengths of this study are the strict inclusion criteria, the relatively large patient population, and the careful monitoring of cardiac complications in the stroke unit. We were also able to confirm all deaths within the series as well as the causes of death. Selection bias is possible, however, because we did not include patients who died on the scene and those who were primarily admitted to the department of neurosurgery for immediate operation. The effect of the exclusion of patients who died on the scene may be insignificant, because the association of ischemic heart disease and atrial fibrillation with the 3-month death rate mostly seemed to manifest Ͼ 2 days after ICH. When the 89 patients who underwent surgery at the neurosurgical department are included, the overall mortality rate rises to 30.4%. Patients with large cerebellar and subcortical hematomas who presented with impaired consciousness were usually treated surgically, with the exception of those already moribund at admission. Almost all of these patients needed intensive care postoperatively. We excluded the patients who needed immediate surgery from the analyses, to avoid bias due to the confounding factors associated with early surgery and intensive care unit treatment. Moreover, it should be noted that the impact of surgery on outcome is still unclear. 10, 15 Thus, the study presents the natural outcome of patients treated conservatively. Another limitation of this study is the lack of data on occasional use of aspirin preceding the onset of stroke. Consequently, some patients classified as nonusers of aspirin may have ingested the drug just before the stroke, which may have worsened their outcome. Such misclassification might underestimate aspirin-associated deaths. Other limitations are the lack of systematic repeated CT scanning of hematomas to detect their enlargement during the acute phase of ICH, and the low autopsy rate.
Conclusions
We found that a history of ischemic heart disease and particularly atrial fibrillation on admission significantly predicted the 1-and 3-month mortality rates in patients with ICH, whereas being on a warfarin regimen predicted 2-day mortality rates. Cardiac complications, including acute MI, were observed more often in patients with than in * Heart disease includes patients with a history of ischemic heart disease as well as those with atrial fibrillation on admission.
† Includes pneumonia, urinary tract infections, and other infections. ‡ Pulmonary embolism and deep venous thrombosis. § Onset of acute MI, heart failure, and arrhythmias during treatment.
those without heart disease. It remains to be resolved in future studies whether resuming antiplatelet or anticoagulant medication soon after the acute phase of ICH in patients with definite indications for these drugs would be beneficial. However, such treatment should certainly be individually tailored.
